

March 2017 APC Decisions

Medicine	Classification	Indication	Other Information
Liothyronine	GREY	Hypothyroid	Changed to grey for all patients with current patients requiring review or referral to an NHS endocrinologist if necessary. Supporting materials to aid review are available via PrescQIPP . Further guidance will be circulated to prescribers in the next few weeks.
Nefopam	AMBER 2	Pain	Restricted for use following renal or pain team initiations only where all other options have been tried or are inappropriate. For further review of use in 6 months time.
Pilocarpine	AMBER 2	Sicca symptoms in patients with Sjogren's syndrome	Prescribing should only transfer to primary care after the dose and efficacy have been established by the initiating specialist.
Sacubitril Valsartan (Entresto® ▼ Novartis)	AMBER 2	Heart Failure	As per NICE . Reclassified following the update of the Nottinghamshire Heart Failure Guidelines and confirmation of place in therapy

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

New to the APC website

- *Heart Failure Traffic Light Treatment Guideline (update)*
- *Rheumatological and Dermatological conditions overarching Shared Care Protocols for DMARDs - (Extension until September 17 due to delay in national guidance update)*
- *Smoking cessation guidelines (update)*

Coming soon to the APC website

- *Continence formulary and guideline (update)*
- *Diabetes guideline (update)*
- *Nebulised Colomycin guideline (update)*
- *Ocular lubricants formulary (new)*

Currently in progress

- *Management of hyperlipidaemia in primary care guideline (New)*
- *Sip feeds guidelines (update)*
- *Medication for managing behavioural problems (new)*

Can you help?

We are currently looking for additional **GP members** to represent the County CCGs. Are you someone with an interest in all things prescribing who is able to commit to attend and contribute at the APC meetings? We meet every 2 months on a Thursday afternoon (2-5pm) at Duncan Macmillan House. Please contact us if you would like to get involved.

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Sodium Chloride 5% PF eye ointment - **Amber 2** to reflect current practice for recurrent corneal erosion.
- Calcium resonium - remains red with a caveat of “primary care prescribing can be undertaken in acute episodes of hyperkalaemia under specialist advice”
- Nifedipress SR - no longer the most cost effective brand. Reference to brands removed from the formulary with a statement to check with medicines management teams for recommended choice.
- Nortriptyline - reclassified to **Amber 3** with reference to the limited place in therapy according to the guidelines for neuropathic pain.

Current work in development

- Prucalopride tablets formulary submission for use in men.
- Emollient Formulary (Review)
- Opicapone formulary submission
- Emarade formulary submission
- Glycopyronium review of licensed products.
- Low priority medicines list (Review)
- GnRH for prostate and breast cancer statement (Review)
- Laxative guidelines for adults (Review)
- Testosterone prescribing and monitoring information (New)
- Melatonin review of formulary status
- ADHD management in adults

Upcoming NICE guidance

Parkinsons' Disease	Guideline	April 2017
COPD - Roflumilast	Technology Appraisal	June 2017
Primary Biliary Cirrhosis - obeticholic acid	Technology Appraisal	June 2017
Etelcalcetide for secondary hyperparathyroidism	Technology Appraisal	June 2017
Asthma management	Guideline	June 2017
Irritable bowel syndrome - Eluxadoline	Technology Appraisal	June 2017

The work of the NAPC is supported and managed by the interface team below. They can be contacted via nottsapc@nottspct.nhs.uk if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Lynne Kennel, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust